ABSTRACT
Because low levels of DNA double strand breaks (DSBs) appear not to activate the ATM-mediated prophase I checkpoint in full-grown oocytes, there may exist mechanisms to protect chromosome integrity during meiotic maturation. Using live imaging we demonstrate that low levels of DSBs induced by the radiomimetic drug Neocarzinostatin (NCS) increase the incidence of chromosome fragments and lagging chromosomes but do not lead to APC/C activation and anaphase onset delay. The number of DSBs, represented by γH2AX foci, significantly decreases between prophase I and metaphase II in both control and NCS-treated oocytes. Transient treatment with NCS increases >2-fold the number of DSBs in prophase I oocytes, but less than 30% of these oocytes enter anaphase with segregation errors. MRE11, but not ATM, is essential to detect DSBs in prophase I and is involved in H2AX phosphorylation during metaphase I. Inhibiting MRE11 by mirin during meiotic maturation results in anaphase bridges and also increases the number of γH2AX foci in metaphase II. Compromised DNA integrity in mirin-treated oocytes indicates a role for MRE11 in chromosome integrity during meiotic maturation.
Subject(s)
DNA Damage/genetics , DNA Repair Enzymes/genetics , DNA-Binding Proteins/genetics , Meiosis/genetics , Oocytes/metabolism , Animals , Ataxia Telangiectasia Mutated Proteins/genetics , DNA Breaks, Double-Stranded/drug effects , DNA Damage/drug effects , Histones/genetics , MRE11 Homologue Protein , Metaphase/genetics , Mice , Oocytes/growth & development , Zinostatin/administration & dosageABSTRACT
The enhanced permeability and retention (EPR) of nanoparticles in tumors has long stood as one of the fundamental principles of cancer drug delivery, holding the promise of safe, simple and effective therapy. By allowing particles preferential access to tumors by virtue of size and longevity in circulation, EPR provided a neat rationale for the trend toward nano-sized drug carriers. Following the discovery of the phenomenon by Maeda in the mid-1980s, this rationale appeared to be well justified by the flood of evidence from preclinical studies and by the clinical success of Doxil. Clinical outcomes from nano-sized drug delivery systems, however, have indicated that EPR is not as reliable as previously thought. Drug carriers generally fail to provide superior efficacy to free drug systems when tested in clinical trials. A closer look reveals that EPR-dependent drug delivery is complicated by high tumor interstitial fluid pressure (IFP), irregular vascular distribution, and poor blood flow inside tumors. Furthermore, the animal tumor models used to study EPR differ from clinical tumors in several key aspects that seem to make EPR more pronounced than in human patients. On the basis of this evidence, we believe that EPR should only be invoked on a case-by-case basis, when clinical evidence suggests the tumor type is susceptible.
Subject(s)
Antineoplastic Agents/administration & dosage , Drug Carriers/chemistry , Nanoparticles , Neoplasms/drug therapy , Animals , Antineoplastic Agents/history , Drug Carriers/history , History, 20th Century , Humans , Maleic Anhydrides/administration & dosage , Maleic Anhydrides/chemistry , Maleic Anhydrides/history , Nanoparticles/chemistry , Neoplasms/pathology , Permeability , Polystyrenes/administration & dosage , Polystyrenes/chemistry , Polystyrenes/history , Zinostatin/administration & dosage , Zinostatin/analogs & derivatives , Zinostatin/chemistry , Zinostatin/historyABSTRACT
Ataxia-telangiectasia (A-T), an autosomal recessive disorder is characterized by progressive neurodegeneration, immunodeficiency, sensitivity to ionizing radiation, and predisposition to cancer, especially to lymphoid malignancies. A-T variant is characterized by a milder clinical phenotype and is caused by missense or leaky splice site mutations that produce residual ataxia telangiectasia mutated (ATM) kinase activity. Lymphoid malignancy can precede the diagnosis of A-T, particularly in young children with mild neurological symptoms. We studied a consanguineous family with four A-T variant patients, three of them developed T-ALL at a young age before the diagnosis of A-T was established. ATM mutation analysis detected two new missense mutations both within exon 12: c.1514T>C and c.1547T>C. All four patients are homozygous for the two mutations, while their parents are heterozygous for the mutations. ATM protein level was low in all patients and the response to the radiomimetic agent, neocarzinostatin, was reduced. Leukemic presentation in a young age in three members of consanguineous family led to the identification of a new missense mutation in the ATM gene. The diagnosis of A-T or A-T variant should be considered in children with neurological abnormalities who develop T-ALL at a young age.
Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Ataxia Telangiectasia Mutated Proteins/genetics , Ataxia Telangiectasia , Mutation, Missense , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Zinostatin/administration & dosage , Adult , Age Factors , Ataxia Telangiectasia/diagnosis , Ataxia Telangiectasia/drug therapy , Ataxia Telangiectasia/genetics , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/geneticsABSTRACT
The patient was a 61-year-old female with alcoholic liver cirrhosis, who was admitted to our hospital due to elevation of AFP.During the evaluation, both abdominal ultrasound and enhanced abdominal CT revealed a hepatocellular carcinoma measuring 4 cm in the S6-7 region, complicated with an arteriovenous shunt.Additionally, the lung CT examination showed 20 isolated bilateral lung tumors, all of which were less than 1.4 cm in diameter. Following the diagnosis, we performed a transcatheter arterial infusion chemotherapy of SMANCS at 3 mg through the right heptic artery. Thereafter, the AFP level returned to normal. Additionally, the tumors previously observed in both liver and lung, and exhibited by both lung CT and enhanced abdominal MRI, had disappeared.The patient has been in clinical remission more than 10 years to date.
Subject(s)
Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Lung Neoplasms/drug therapy , Maleic Anhydrides/therapeutic use , Polystyrenes/therapeutic use , Zinostatin/analogs & derivatives , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/pathology , Disease-Free Survival , Female , Humans , Infusions, Intra-Arterial , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Magnetic Resonance Imaging , Maleic Anhydrides/administration & dosage , Middle Aged , Polystyrenes/administration & dosage , Time Factors , Tomography, X-Ray Computed , Zinostatin/administration & dosage , Zinostatin/therapeutic useABSTRACT
The treatment for metastatic renal cell carcinoma (RCC) has changed dramatically after the beginning of molecular-targeted therapies. However,the treatment for liver metastasis is still difficult in patients with metastatic RCC. We treated liver metastases (8 target lesions) of RCC with stylene-maleic acid neocarzinostatin (SMANCS)/Lipiodol therapy. At the treatment procedure,a catheter was inserted at the femoral artery (Seldinger's method),a microcatheter was selectively inserted into the branch of hepatic artery which fed the liver metastasis,and then SMANCS/Lipodol was infused. We treated 1,2 and 1 patient 4,2, and 1 time,respectively. One lesion treated with SMANCS/Lipodol was further treated by radiofrequency ablation 13 days later. Of 6 metastatic lesions which could be followed up for more than 6 months after the treatment,one had partial response for 4 months and 4 had stable disease for more than 6 months. Four of the 6 lesions shrunk after SMANCS/Lipiodol treatment. Two of 4 patients survived more than 18 months after the first SMANCS/Lipiodol therapy. In all 9 SMANCS/Lipiodol treatments,grade 1 liver dysfunction (44.4%),ascites (11.1%) and fatigue (11.1%) occurred after the treatments. These adverse events were all improved by conservative treatments. SMANCS/Lipiodol therapy can be a treatment option as local treatment for liver metastasis of RCC.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Renal Cell/pathology , Ethiodized Oil/administration & dosage , Kidney Neoplasms/pathology , Liver Neoplasms/drug therapy , Maleic Anhydrides/administration & dosage , Polystyrenes/administration & dosage , Zinostatin/analogs & derivatives , Adult , Aged , Female , Humans , Infusions, Intra-Arterial , Male , Middle Aged , Zinostatin/administration & dosageABSTRACT
OBJECTIVE: Although iodized oil transarterial chemoembolization (TACE) has been found to have survival benefit in the care of patients with unresectable hepatocellular carcinoma, iodized oil infusion chemotherapy without embolization has not been clearly found inferior to or equal to TACE. The purpose of this study was to determine whether one of these therapies is superior to the other or the two are equal in survival benefit and whether embolization with gelatin sponge particles is indispensable to prolonging survival. SUBJECTS AND METHODS: A prospective nonrandomized observational cohort study was conducted over 8 years. Among 11,030 patients with unresectable hepatocellular carcinoma, 8,507 underwent TACE, and 2,523 underwent transarterial infusion therapy with an emulsion of iodized oil and an anticancer agent as initial treatment. Patients with extrahepatic metastasis or any previous treatment were excluded. The primary end point was all-cause mortality. To minimize selection bias, propensity score analysis was used to compare the two groups. RESULTS: During the follow-up period, 5,044 patients (46%) died. In the analysis of all patients, TACE was associated with a significantly higher survival rate than infusion therapy without embolization (hazard ratio, 0.60; 95% CI, 0.56-0.64; p = 0.0001). The propensity score analysis showed that the hazard ratio for death in the TACE group (n = 1,699 patients) compared with the group who underwent infusion therapy without embolization (n = 1,699) was 0.70 (95% CI, 0.63-0.76; p = 0.0001). The median survival time of the TACE group was 2.74 years, and the 1-, 3-, and 5-year survival rates were 81%, 46%, and 25%. The corresponding values for the group who underwent transarterial infusion therapy without embolization were 1.98 years and 71%, 33%, and 16%. CONCLUSION: Propensity score analysis showed that in the treatment of patients with unresectable hepatocellular carcinoma, TACE was associated with significantly better overall survival rates than was transarterial infusion therapy without embolization. TACE can be recommended as initial treatment of these patients.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Chemoembolization, Therapeutic , Iodized Oil/therapeutic use , Liver Neoplasms/drug therapy , Aged , Biomarkers, Tumor/analysis , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Chi-Square Distribution , Cisplatin/administration & dosage , Combined Modality Therapy , Diagnostic Imaging , Doxorubicin/administration & dosage , Epirubicin/administration & dosage , Female , Humans , Liver Neoplasms/diagnosis , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Logistic Models , Male , Middle Aged , Mitomycin/administration & dosage , Neoplasm Invasiveness , Neoplasm Staging , Proportional Hazards Models , Prospective Studies , Surveys and Questionnaires , Survival Rate , Treatment Outcome , Zinostatin/administration & dosageABSTRACT
A case of hepatocellular carcinoma, successfully treated with multimodal loco-regional treatments, is reported. An 80-year-old male presented with multiple pulmonary and peritoneal metastases 4 months after right heimihepatectomy for ruptured HCC. Bronchial artery infusion of mitomycin C induced pulmonary tumor regression and stabilization. Peritoneal tumor was treated by arterial infusion of SMANCS, followed by percutaneous injection of absolute ethanol, which ended in surgical removal in 28-postoperative month due to abscess formation. He had been well until right adrenal and left pulmonary metastases appeared. Resection of both metastases was carried out in 39-post hepatectomy month. Recurrent left pulmonary metastasis was treated with two sessions of bronchial artery infusion with no effect this time. Video-assisted partial resection of the left lung was performed in 54 post-hepatectomy month. But his AFP level kept rising. Eventually pulmonary metastasis recurred and tumor thrombus reached the left atrium 58 months after hepatectomy. He wanted no more treatment. He died of cerebral infarction caused by tumor thrombus. He enjoyed a good QOL for five years through multimodal loco-regional treatments.
Subject(s)
Carcinoma, Hepatocellular/pathology , Ethanol/administration & dosage , Liver Neoplasms/pathology , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Peritoneal Neoplasms/secondary , Peritoneal Neoplasms/therapy , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Bronchial Arteries , Carcinoma, Hepatocellular/surgery , Hepatectomy , Humans , Infusions, Intra-Arterial , Injections, Intralesional , Liver Neoplasms/surgery , Male , Maleic Anhydrides/administration & dosage , Mitomycin/administration & dosage , Polystyrenes/administration & dosage , Zinostatin/administration & dosage , Zinostatin/analogs & derivativesABSTRACT
BACKGROUND/AIMS: Transcatheter arterial chemoembolization (TACE) is a combination of transarterial infusion chemotherapy (TAI) and embolization, and has been widely used to treat patients with hepatocellular carcinoma (HCC). However, since the impact of adding embolization on the survival of patients treated with TAI had never been evaluated in a phase III study, we conducted a multi-center, open-label trial comparing TACE and TAI to assess the effect of adding embolization on survival. METHODS: Patients with newly diagnosed unresectable HCC were randomly assigned to either a TACE group or a TAI group. Zinostatin stimalamer was injected into the hepatic artery, together with gelatin sponge in the TACE group and without gelatin sponge in the TAI group. Treatment was repeated when follow-up computed tomography showed the appearance of new lesions in the liver or re-growth of previously treated tumors. RESULTS: Seventy-nine patients were assigned to the TACE group, and 82 were assigned to the TAI group. The two groups were comparable with respect to their baseline characteristics. At the time of the analysis, 51 patients in the TACE group and 58 in the TAI group had died. The median overall survival time was 646 days in the TACE group and 679days in the TAI group (p=0.383). CONCLUSIONS: The results of this study suggest that treatment intensification by adding embolization did not increase survival over TAI with zinostatin stimalamer alone in patients with HCC.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic , Liver Neoplasms/drug therapy , Liver Neoplasms/therapy , Adult , Aged , Antineoplastic Agents/adverse effects , Carcinoma, Hepatocellular/mortality , Chemoembolization, Therapeutic/adverse effects , Female , Humans , Infusions, Intra-Arterial , Liver Neoplasms/mortality , Male , Maleic Anhydrides/administration & dosage , Maleic Anhydrides/adverse effects , Middle Aged , Polystyrenes/administration & dosage , Polystyrenes/adverse effects , Survival Rate , Zinostatin/administration & dosage , Zinostatin/adverse effects , Zinostatin/analogs & derivativesABSTRACT
The purpose of this study is to evaluate the improved method of arterial infusion therapy of SMANCS (SX) with lipiodol under the angiotensin-induced hypertensive state for various difficult-to-treat solid tumors. Most patients were unresectable with no other therapeutic options, recurrence after resection, or patients do not respond to common treatments. The new method utilizes angiotensin II (AT) to induce hypertension (e.g. approximately 15-30 mmHg above norm) for 15-20 min. This method was successfully applied to metastatic liver cancer, cholangiocarcinoma, massive renal cell carcinoma, pancreatic and other abdominal solid cancers. This AT-induced hypertension resulted in remarkably enhanced tumor delivery accompanied by improved therapeutic response, and a shorter time to achieve 50% regression of tumor size with least toxicity. We demonstrated clinically herein improved therapy for various advanced solid tumors with SX by elevating the tumor blood flow selectively. This is the first clinical proof that modulations of vascular pathophysiology can uniquely accomplish enhanced tumor selective delivery of polymeric drugs and thus yielded better clinical outcome.
Subject(s)
Angiotensin II/administration & dosage , Antineoplastic Agents/administration & dosage , Blood Pressure/drug effects , Hypertension/chemically induced , Maleic Anhydrides/administration & dosage , Neoplasms/blood supply , Neoplasms/drug therapy , Polystyrenes/administration & dosage , Vasoconstrictor Agents/administration & dosage , Zinostatin/analogs & derivatives , Adenocarcinoma/drug therapy , Adult , Aged , Carcinoma, Renal Cell/drug therapy , Cholangiocarcinoma/drug therapy , Drug Delivery Systems , Female , Humans , Infusions, Intravenous , Japan , Kidney Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Male , Middle Aged , Neoplasm Staging , Neoplasms/pathology , Ovarian Neoplasms/drug therapy , Pancreatic Neoplasms/drug therapy , Zinostatin/administration & dosageABSTRACT
The size of anticancer agent-incorporating micelles can be controlled within the diameter range of 20-100 nm to ensure that they do not penetrate normal vessel walls. With this development, it is expected that the incidence of drug-induced side-effects may be decreased owing to the reduced drug distribution in normal tissue. Micelle systems can also evade non-specific capture by the reticuloendothelial system because the outer shell of a micelle is covered with polyethylene glycol. Consequently, a polymer micelle carrier can be delivered selectively to a tumor by utilizing the enhanced permeability and retention effect. Moreover, a water-insoluble drug can be incorporated into polymer micelles. Presently, several anticancer agent-incorporating micelle carrier systems are under preclinical and clinical evaluation. Furthermore, nucleic acid-incorporating micelle carrier systems are also being developed.
Subject(s)
Antineoplastic Agents/administration & dosage , Micelles , Polymers/chemistry , Animals , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/pharmacology , Antineoplastic Agents/pharmacology , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/pharmacology , Clinical Trials as Topic , Doxorubicin/administration & dosage , Doxorubicin/pharmacology , Drug Carriers/chemistry , Drug Delivery Systems , Drug Evaluation, Preclinical , Humans , Nanoparticles/chemistry , Paclitaxel/administration & dosage , Paclitaxel/analogs & derivatives , Paclitaxel/pharmacology , Particle Size , Polyethylene Glycols/chemistry , Zinostatin/administration & dosage , Zinostatin/pharmacologyABSTRACT
The monoclonal antibody A7 (Mab A7) against human colonic cancer also reacts with human gastric cancer at a high rate. We produced a conjugate of neocarzinostatin (NCS) with Mab A7 (A7-NCS). The in vitro anticancer effect of A7-NCS on the antigen-positive human gastric cancer cell line MKN45 was stronger than that of free NCS. Nude mice models of peritoneal dissemination were established by the intra-peritoneal inoculation of MKN45. These models were divided into three groups. The anticancer effect observed in the group that received the intra peritoneal injection of A7-NCS was superior to that observed in the group that received the intra-venous injection and the group that received no treatment. In conclusion, the intra-peritoneal injection of A7-NCS was a useful treatment method for the peritoneal dissemination of gastric cancer.
Subject(s)
Adenocarcinoma/immunology , Antibiotics, Antineoplastic/administration & dosage , Antibodies, Monoclonal/administration & dosage , Antigens, Neoplasm/immunology , Neoplasm Seeding , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/secondary , Stomach Neoplasms/drug therapy , Zinostatin/administration & dosage , Animals , Cell Line, Tumor , Humans , Infusions, Parenteral , Injections, Intravenous , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Stomach Neoplasms/pathologyABSTRACT
Tumor targeting therapy, that is "Missile therapy", using a complex composed of a tumor suppressive drug and a whole antibody against tumor cells, is expected to become an attractive chemotherapy strategy. However, clinically convincing results have not yet been obtained mainly due to poor transport from the circulation to tumor tissue and marked toxicity. Recently, recombinant immunotoxins, composed of an Fv fragment of an antibody to a tumor-related antigen fused to various truncated toxins have been developed to overcome the distribution of immunotoxins in tumors. These recombinant immunotoxins have shown encouraging clinical results for some hematopoietic malignancies. However, there were no significant anti-tumor responses to many tumors, especially solid tumors, probably due to their rapid clearance from the circulation and their immunogenicity and antigenicity. More recently, PEGylation of recombinant immunotoxins has been attempted to overcome these drawbacks. It was found that PEGylation of recombinant immunotoxins improves their effectiveness. We discuss the recent progress in tumor missile therapy. In contrast to others, we developed "Missile therapy against tumor blood vessels" by using specific monoclonal antibodies against tumor endothelial cells rather than actual tumor cells. The complex between antibodies to tumor vascular endothelial cells and anti-tumor drugs can freely access the target cells without concern for their vascular permeability. These preparations have exhibited excellent anti-tumor effects for solid tumors. In this review, we also discuss this vascular targeting therapy as an attractive new strategy for tumor chemotherapy.
Subject(s)
Endothelial Cells/physiology , Immunoconjugates/therapeutic use , Immunotoxins/therapeutic use , Neoplasms/blood supply , Neoplasms/therapy , Animals , Antibodies, Monoclonal/therapeutic use , Humans , Interleukin-6/therapeutic use , Polyethylene Glycols/therapeutic use , Recombinant Proteins/therapeutic use , Zinostatin/administration & dosageABSTRACT
A 55-year-old female was admitted to our hospital for a third recurrence of hepatoma. She was treated with transcatheter arterial embolization (TAE) in April and November 1996. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed multiple tumors of S4/S8 and S7 in the liver. After the third TAE using SMANCS, Lipiodol and Spongel, abdominal CT revealed insufficient Lipiodol retention and the in efficacy of this treatment. A right lobectomy of the liver was performed for the TAE resistant multiple recurrence of HCC. After the surgery, the patient survived for over 5 years with no recurrence. It appears that this surgery may be a useful modality for TAE resistant multiple recurrence hepatoma in cases of good liver function and lesions limited to the hemi lobe.
Subject(s)
Carcinoma, Hepatocellular/surgery , Hepatectomy , Liver Neoplasms/surgery , Neoplasm Recurrence, Local/surgery , Zinostatin/analogs & derivatives , Antineoplastic Agents/administration & dosage , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/therapy , Embolization, Therapeutic , Female , Humans , Iodized Oil/administration & dosage , Liver Neoplasms/pathology , Liver Neoplasms/therapy , Maleic Anhydrides/administration & dosage , Middle Aged , Polystyrenes/administration & dosage , Survivors , Zinostatin/administration & dosageABSTRACT
BACKGROUND: Hepatic arterial infusion of zinostatin stimalamer and lipiodol emulsion shows a moderate activity against hepatocellular carcinoma. However, the anti-tumor activity of zinostatin stimalamer alone is uncertain. METHODS: The primary endpoint was to evaluate the frequency of dose-limiting toxicity and determine the maximum-tolerated dose of zinostatin stimalamer when used by intra-arterial infusion. The candidates for this study were patients with hepatocellular carcinoma no longer amenable to established forms of treatment. Hepatic arterial infusion chemotherapy was performed by selectively introducing a catheter into the hepatic artery with zinostatin stimalamer alone. Treatment was repeated at 4-8-week intervals until disease progression or the appearance of unacceptable toxicity. The starting dose of zinostatin stimalamer was 3 mg/m(2), and doses were increased in 1 mg/m(2) increments in successive cohorts. At least three patients were treated at each dose level and three additional patients were treated in the presence of dose-limiting toxicity. RESULTS: Twelve patients were entered into this trial. Dose-limiting toxicity was observed in one of six patients at 3 mg/m(2), and in two of six patients at 4 mg/m(2). The maximum-tolerated dose was judged to be 3 mg/m(2) with liver dysfunction and serum creatinine increase as the dose-limiting toxicity. There was one early death suggested to be related to the protocol treatment. None of the 12 patients achieved an objective tumor response. CONCLUSION: Hepatic arterial infusion with a zinostatin stimalamer of 3 mg/m(2) may be tolerated, but not active, in patients with far advanced hepatocellular carcinoma.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Maleic Anhydrides/administration & dosage , Polystyrenes/administration & dosage , Zinostatin/analogs & derivatives , Zinostatin/administration & dosage , Aged , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Hepatic Artery , Humans , Infusions, Intra-Arterial , Iodized Oil/administration & dosage , Male , Middle AgedSubject(s)
Antineoplastic Agents/adverse effects , Carcinoma, Hepatocellular/therapy , Granuloma/chemically induced , Liver Neoplasms/therapy , Maleic Anhydrides/adverse effects , Polystyrenes/adverse effects , Zinostatin/adverse effects , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Antineoplastic Agents/administration & dosage , CD8 Antigens/analysis , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Chemoembolization, Therapeutic , Granuloma/diagnostic imaging , Granuloma/pathology , Humans , Immunohistochemistry , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Male , Maleic Anhydrides/administration & dosage , Middle Aged , Polystyrenes/administration & dosage , Tomography, X-Ray Computed , Zinostatin/administration & dosage , Zinostatin/analogs & derivativesABSTRACT
Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). In our previous study, transcatheter arterial infusion chemotherapy using SMANCS for HCC showed a response rate of 20%. In an effort to obtain a superior anti-tumor effect against HCC, we conducted a phase II study of transcatheter arterial embolization (TAE) using SMANCS and gelatin sponge in 50 chemotherapy-naive patients with HCC. Four milligrams SMANCS plus 4 ml lipiodol emulsion was injected into the hepatic artery, followed by an injection of gelatin sponge. The responses were evaluated by computed tomography (CT) 1 month after treatment and thereafter every 3-4 months. One patient (2%) showed complete response and 15 patients (30%) had partial response resulting in an overall response rate of 32% (16/50; 95% confidence interval 19-45%). In 33 patients (66%), the disease remained stable, and 1 patient (2%) showed progressive disease. In 35 patients (70%), the rate of necrotic area to whole tumor was more than 50% according to the evaluation method using lipiodol accumulation in CT. The 1-, 3- and 5-year survival rates were 90, 55 and 19%, respectively. Grade 3 hematological toxicity was observed as thrombocytopenia in 2 patients (4%). Grade 3 and 4 non-hematological toxicity (liver dysfunction) occurred in 17 (34%) and 7 patients (14%), respectively. TAE using SMANCS, which was well tolerated, may be an effective treatment for advanced HCC.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic , Liver Neoplasms/therapy , Maleic Anhydrides/administration & dosage , Polystyrenes/administration & dosage , Zinostatin/administration & dosage , Adult , Aged , Antineoplastic Agents/adverse effects , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Female , Humans , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Male , Maleic Anhydrides/adverse effects , Middle Aged , Polystyrenes/adverse effects , Survival Rate , Treatment Outcome , Zinostatin/adverse effects , Zinostatin/analogs & derivativesABSTRACT
To evaluate the effect of styrene maleic neocarzinostatin-transcatheter arterial embolization (SMANCS-TAE), 40 patients with unresectable hepatocellular carcinoma (HCC) of hypervascular radiological feature, associated with liver cirrhosis (LC), 18 in clinical stage 2 and 20 in stage 3, were treated by SMANCS-TAE. SMANCS with Lipiodol and then gelatin sponge particles were injected into the artery branch supplying HCC using selective catheterization, and its effect was evaluated by computed tomography (CT) Grade. In patients with Grade III or less (Lipiodol accumulation < 99% in the entire tumor) after the first course of therapy, SMANCS-TAE or arterial injection of SMANCS-Lipiodol was performed once or twice more. Consequently, 32 of 40 patients (80%) obtained Grade IV (100% Lipiodol accumulation in the entire tumor) after from once to thrice (median, 1.6 courses). Grade IV was maintained in 26 of 32 patients, and non-recurrence was found 16 of 40 (40%) at the primary tumor to the time at last of follow up. Severe side effects were not noted except in 10 cases with narrowness of hepatic artery and cases of 2 biloma in patients undergoing therapy two or more times. The 1-, 2-, 3-, and 5-year survival rate was 85, 64, 35, and 26%, respectively. No significant difference was noted in the survival rate between clinical stage 2 and 3 liver cirrhosis (LC). But the survival rate of patients who continued to exhibit Grade IV at the primary tumor was significantly better than in those exhibiting Grade III or less (96, 68, 56, and 43% vs 64, 29, 0, and 0%, respectively; p < 0.01). In conclusion, the HCC patients, even those with decompensated LC, who obtained and maintained Grade IV after SMANCS-TAE could reduce the courses of treatment without severe side effects and survived longer. SMANCS-TAE might be useful for the good quality of life of HCC patients.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Hepatocellular/therapy , Embolization, Therapeutic , Liver Neoplasms/therapy , Maleic Anhydrides/administration & dosage , Polystyrenes/administration & dosage , Zinostatin/administration & dosage , Aged , Carcinoma, Hepatocellular/mortality , Embolization, Therapeutic/methods , Female , Humans , Iodized Oil/administration & dosage , Liver Neoplasms/mortality , Male , Middle Aged , Survival Rate , Zinostatin/analogs & derivativesABSTRACT
A7-NCS, which is a conjugate of the monoclonal antibody A7 against a human colonic cancer and the anticancer agent neocarzinostatin (NCS), reacts with human gastric cancers at a high rate. The anticancer effect of A7-NCS is stronger than that of free NCS. Nude mice models of peritoneal dissemination were established simply by intra-peritoneal inoculation of the antigen-positive human gastric cancer cell line MKN45. Using these models, the anticancer effect of A7-NCS against the peritoneal dissemination of gastric cancer was examined. The murine peritoneal dissemination models were divided into three groups. The anticancer effect of the group injected intra-peritoneally with A7-NCS 2 days after cancer inoculation was compared with that injected 18 days after inoculation. The anticancer effect in the 18-day group was inferior to that in the 2-day group, but was superior to that in the non-treated group. To get a better result in the 18-day group, which is in the advanced stage of peritoneal dissemination, repeated injection and the dose of A7-NCS should be examined.
Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Immunotoxins/administration & dosage , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/secondary , Stomach Neoplasms/drug therapy , Zinostatin/administration & dosage , Animals , Antibodies, Monoclonal , Humans , Mice , Mice, Nude , Stomach Neoplasms/pathologyABSTRACT
This review article describes three aspects of polymeric drugs. The general mechanism of the EPR (enhanced permeability and retention) effect and factors involved in the effect are discussed, in view of the advantages of macromolecular therapeutics for cancer treatment, which are based on the highly selective EPR-related delivery of drug to tumor. Also described are advantages of more general water-soluble polymeric drugs as primary anticancer agents, using SMANCS as an example. Last, SMANCS/Lipiodol is discussed with reference to the type of formulation for arterial injection with most pronounced tumor selective delivery, as well as its advantages, precautions, and side effects from the clinical standpoint.
Subject(s)
Antineoplastic Agents/pharmacology , Drug Delivery Systems , Maleic Anhydrides/pharmacology , Polystyrenes/pharmacology , Zinostatin/analogs & derivatives , Zinostatin/pharmacology , Amino Acid Sequence , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Humans , Macromolecular Substances , Maleic Anhydrides/administration & dosage , Maleic Anhydrides/pharmacokinetics , Molecular Sequence Data , Permeability , Polystyrenes/administration & dosage , Polystyrenes/pharmacokinetics , Zinostatin/administration & dosage , Zinostatin/pharmacokineticsABSTRACT
To clarify the effect of SMANCS on malignant pleural carcinomatosis, seven patients with malignant pleural effusion were treated with SMANCS administered via an intracavitary route. Five patients showed improvement after one or two injections of SMANCS into the thoracic cavity, although 2 patients needed further therapy with the immunopotentiating agent picibanil (OK-432). No serious adverse effects were observed. This simple therapeutic tactic with SMANCS may be effective in cases of malignant pleural carcinomatosis.